233 related articles for article (PubMed ID: 17184801)
1. Silymarin and epithelial cancer chemoprevention: how close we are to bedside?
Kaur M; Agarwal R
Toxicol Appl Pharmacol; 2007 Nov; 224(3):350-9. PubMed ID: 17184801
[TBL] [Abstract][Full Text] [Related]
2. Silymarin and hepatocellular carcinoma: a systematic, comprehensive, and critical review.
Mastron JK; Siveen KS; Sethi G; Bishayee A
Anticancer Drugs; 2015 Jun; 26(5):475-86. PubMed ID: 25603021
[TBL] [Abstract][Full Text] [Related]
3. Chemopreventive efficacy of silymarin in skin and prostate cancer.
Deep G; Agarwal R
Integr Cancer Ther; 2007 Jun; 6(2):130-45. PubMed ID: 17548792
[TBL] [Abstract][Full Text] [Related]
4. Multitargeted therapy of cancer by silymarin.
Ramasamy K; Agarwal R
Cancer Lett; 2008 Oct; 269(2):352-62. PubMed ID: 18472213
[TBL] [Abstract][Full Text] [Related]
5. Toward the definition of the mechanism of action of silymarin: activities related to cellular protection from toxic damage induced by chemotherapy.
Comelli MC; Mengs U; Schneider C; Prosdocimi M
Integr Cancer Ther; 2007 Jun; 6(2):120-9. PubMed ID: 17548791
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer.
Ting H; Deep G; Agarwal R
AAPS J; 2013 Jul; 15(3):707-16. PubMed ID: 23588585
[TBL] [Abstract][Full Text] [Related]
7. Anti-angiogenic potential of a cancer chemopreventive flavonoid antioxidant, silymarin: inhibition of key attributes of vascular endothelial cells and angiogenic cytokine secretion by cancer epithelial cells.
Jiang C; Agarwal R; Lü J
Biochem Biophys Res Commun; 2000 Sep; 276(1):371-8. PubMed ID: 11006131
[TBL] [Abstract][Full Text] [Related]
8. Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells.
Cufí S; Bonavia R; Vazquez-Martin A; Corominas-Faja B; Oliveras-Ferraros C; Cuyàs E; Martin-Castillo B; Barrajón-Catalán E; Visa J; Segura-Carretero A; Bosch-Barrera J; Joven J; Micol V; Menendez JA
Food Chem Toxicol; 2013 Oct; 60():360-8. PubMed ID: 23916468
[TBL] [Abstract][Full Text] [Related]
9. Targeting STAT3 with silibinin to improve cancer therapeutics.
Bosch-Barrera J; Queralt B; Menendez JA
Cancer Treat Rev; 2017 Jul; 58():61-69. PubMed ID: 28686955
[TBL] [Abstract][Full Text] [Related]
10. Chemoprevention of cancer by isothiocyanates and anthocyanins: mechanisms of action and structure-activity relationship.
Fimognari C; Lenzi M; Hrelia P
Curr Med Chem; 2008; 15(5):440-7. PubMed ID: 18288999
[TBL] [Abstract][Full Text] [Related]
11. Silibinin and its 2,3-dehydro-derivative inhibit basal cell carcinoma growth via suppression of mitogenic signaling and transcription factors activation.
Tilley C; Deep G; Agarwal C; Wempe MF; Biedermann D; Valentová K; Kren V; Agarwal R
Mol Carcinog; 2016 Jan; 55(1):3-14. PubMed ID: 25492239
[TBL] [Abstract][Full Text] [Related]
12. A cancer chemopreventive agent silibinin, targets mitogenic and survival signaling in prostate cancer.
Singh RP; Agarwal R
Mutat Res; 2004 Nov; 555(1-2):21-32. PubMed ID: 15476849
[TBL] [Abstract][Full Text] [Related]
13. Flavonoid antioxidant silymarin and skin cancer.
Singh RP; Agarwal R
Antioxid Redox Signal; 2002 Aug; 4(4):655-63. PubMed ID: 12230878
[TBL] [Abstract][Full Text] [Related]
14. Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts.
Kidd PM
Altern Med Rev; 2009 Sep; 14(3):226-46. PubMed ID: 19803548
[TBL] [Abstract][Full Text] [Related]
15. Targeting silibinin in the antiproliferative pathway.
Li L; Zeng J; Gao Y; He D
Expert Opin Investig Drugs; 2010 Feb; 19(2):243-55. PubMed ID: 20047507
[TBL] [Abstract][Full Text] [Related]
16. The Pros and the Cons for the Use of Silybin-Rich Oral Formulations in Treatment of Liver Damage (NAFLD in Particular).
Rosso N; Marin V; Giordani A; Persiani S; Sala F; Cavicchioli L; Rovati LC; Tiribelli C
Curr Med Chem; 2015; 22(25):2954-71. PubMed ID: 26219393
[TBL] [Abstract][Full Text] [Related]
17. Silymarin and skin cancer prevention: anti-inflammatory, antioxidant and immunomodulatory effects (Review).
Katiyar SK
Int J Oncol; 2005 Jan; 26(1):169-76. PubMed ID: 15586237
[TBL] [Abstract][Full Text] [Related]
18. Advances in prostate cancer chemoprevention: a translational perspective.
Nambiar D; Singh RP
Nutr Cancer; 2013; 65 Suppl 1():12-25. PubMed ID: 23682779
[TBL] [Abstract][Full Text] [Related]
19. Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy.
Bosch-Barrera J; Menendez JA
Cancer Treat Rev; 2015 Jun; 41(6):540-6. PubMed ID: 25944486
[TBL] [Abstract][Full Text] [Related]
20. Chemopreventive and anti-cancer efficacy of silibinin against growth and progression of lung cancer.
Mateen S; Raina K; Agarwal R
Nutr Cancer; 2013; 65 Suppl 1(0 1):3-11. PubMed ID: 23682778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
